Re: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years
- PMID: 32141803
- DOI: 10.1097/JU.0000000000001008
Re: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years
Comment in
-
Reply by Authors.J Urol. 2020 Jul;204(1):158-159. doi: 10.1097/JU.0000000000001009. Epub 2020 Mar 6. J Urol. 2020. PMID: 32149568 No abstract available.
Comment on
-
Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.Eur Urol. 2019 Jul;76(1):98-105. doi: 10.1016/j.eururo.2018.12.030. Epub 2019 Jan 9. Eur Urol. 2019. PMID: 30638633
-
Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer.BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18. BJU Int. 2019. PMID: 30753756
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical